GoldenGolden
Sarepta Therapeutics

Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company founded by Marwan Fawaz in 1980 and headquartered in Cambridge, Massachusetts developing precision genetic medicines for the treatment of rare neuromuscular diseases.

Contents
Partners
Timeline
Funding rounds
Products
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Serepta Therepeutics, formerly AVI BioPharma, is a biotechnology company that is headquartered in Cambridge, Massachusetts, and was founded in 1980 by Marwan Fawaz. The company is developing gene therapies and medicines for the treatment of neuromuscular diseases such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD), and Charcot-Marie-Tooth (CMT). Serepta Therapeutics creates their gene therapies and medicines using multiple therapeutic approaches which include RNA, gene therapy, and gene editing.

Partners

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
‌
Sarepta Therapeutics, Inc. funding round, November 2019
30,499,980
November 2019
‌
Sarepta Therapeutics, Inc. funding round, February 2020
399,999,980
February 2020
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Amit Patel

Investor

Bo Cumbo

Senior Vice President & Chief Commercial Officer

Bruce Girton

Employee

Diane Berry

Vice President, Global Health Policy and Government Affairs

Douglas Ingram

President and CEO

Gary Charbonneau

Senior Vice President, Global Regulatory Affairs

Gilmore O'Neill

Senior Vice President, R&D and Chief Medical Officer

Ian Estepan

Chief of Staff, Vice President, Corporate Affairs

Jason Gatlin

Employee

Joan Nickerson

Vice President, Human Resources

Louise Rodino-Klapac

Vice President, Gene Therapy

Quinn Viens

Employee

Sagar Desai

Employee

Sandy Mahatme

Executive Vice President, CFO & CBO

Sarah Higgins

Employee

suchith nareddy

Employee

Ty Howton

Senior Vice president, General Counsel and Corporate Strategy

Further reading

Title
Author
Link
Type
Date

Sarepta Therapeutics enters manufacturing partnership for DMD treatment

Maggie Lynch

https://www.biopharma-reporter.com/Article/2018/10/17/Sarepta-Therapeutics-enters-manufacturing-partnership-for-DMD-treatment

Web

Sarepta Therapeutics shares soar 50% on positive preliminary results for muscular dystrophy gene therapy

Angelica LaVito

https://www.cnbc.com/2018/06/19/sarepta-therapeutics-shares-soar-on-preliminary-gene-therapy-data.html

News

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Sarepta bags drug to fully unlock DMD gene therapy opportunity
Nick Paul
July 2, 2020
FierceBiotech
Sarepta Therapeutics has secured a license to a drug that could enable more patients to receive its gene therapies. The deal grants Sarepta the exclusive right to use Hansa Biopharma's imlifidase to eliminate neutralizing antibodies in Duchenne muscular dystrophy and limb-girdle muscular dystrophy patients.
Sarepta's Gene Therapy for Limb-Girdle Muscular Dystrophy Shows Promise
Mark Terry
June 9, 2020
BioSpace
On Monday, Sarepta Therapeutics announced positive results from a small study of SRP-9003, its gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
BioSpace
June 8, 2020
BioSpace
-- In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase in transduction and expression when compared with the low-dose cohort, with a mean of 72% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 50% measure for success -- -- A mean signal intensity of 73% in the high-dose group was observed compared to normal control -- -- A mean beta-sarcoglycan
Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
BioSpace
May 11, 2020
BioSpace
Agreement leverages Sarepta's leadership in gene therapy for neuromuscular and cardiovascular diseases and Dyno's CapsidMap artificial intelligence platform to design AAV vectors
Dyno Explodes Out of Stealth Mode with $2 Billion in Deals with Biopharma Companies
Mark Terry
May 11, 2020
BioSpace
Dyno says that with its research-and-development and collaboration deals with biopharma companies, it is potentially eligible for more than $2 billion in upfront payments, research support, and various milestones and option fees.
Roche enters $1.15 billion licensing deal for Sarepta gene therapy
Reuters Editorial
December 23, 2019
U.S.
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.

References

sarepta.com
Is a
Company

Company attributes

Industry
Biotechnology
Genetic engineering
Gene therapy
Healthcare
Pharmaceutical industry
Drug discovery
‌
Biopharmaceutical
‌
Therapeutics
Location
Cambridge, Massachusetts
Corvallis, Oregon
Andover, Massachusetts
United States
CEO
‌
Douglas S. Ingram
Founder
‌
Marwan Fawaz
Crunchbase
crunchbase.com/organiz...apeutics
Date incorporated
1980
CIK number
873,303
Place of incorporation
Massachusetts
IRS number
930,797,222
Founded date
1980
Total funding amount (USD)
430,499,960
Stock symbol
SRPT
Stock exchange
NASDAQ

Other attributes

Country
United States
Headquarters
Cambridge, Massachusetts
Market
Biotechnology
SIC code
2,834

Categories

Related Topics

Contributors

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
FeaturesPricingEnterprise
Legal
Terms & ConditionsPrivacy Policy
Help
Help centerAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.